Simuni T, on behalf of the Parkinson Study Group. A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Final study results. AAN 2019.
Biobank ideale bron voor onderzoek naar COVID-19
sep 2020 | Dementie, Multipele Sclerose, Neuro-musculair